Buprenorphine plays a crucial role in the therapeutic management of pain in adults,
adolescents and pediatric subpopulations. However, only few pharmacokinetic studies of …

Neonatal opioid withdrawal syndrome (NOWS) is a major public health concern whose
incidence has paralleled the opioid epidemic in the United States. Sublingual …

Aims Opioid dependence is associated with high morbidity and mortality. Buprenorphine
(BUP) is approved by the Food and Drug Administration to treat opioid dependence. There …

Fentanyl is widely used for analgesia, sedation, and anesthesia both in adult and pediatric
populations. Yet, only few pharmacokinetic studies of fentanyl in pediatrics exist as …

Aims Buprenorphine (BUP) is approved by the US Food and Drug Administration for the
treatment of opioid addiction. The current dosing regimen of BUP in pregnant women is …

Objective Neonatal abstinence syndrome (NAS)—a clinical entity of infants from in utero
exposure to psychoactive xenobiotic and buprenorphine—has been successfully used to …

Neonatal abstinence syndrome (NAS) is a condition affecting newborns that are exposed to
an opioid in utero. In a randomized, controlled trial assessing the efficacy of buprenorphine …

The use of physiologically based pharmacokinetic (PBPK) models in the field of pediatric
drug development has garnered much interest of late due to a recent Food and Drug …

Purpose Physiologically-based pharmacokinetic (PBPK) modeling offers a unique modality
to predict age-specific pharmacokinetics. The objective of this study was to assess the ability …

In recent years, the increased interest in pediatric research has enforced the role of
physiologically based pharmacokinetic (PBPK) models in pediatric drug development …